So let's move on. We are not under a hold for NASH
Post# of 148158
I would personally like to concentrate on looking for partnerships and buyouts and instead of the concentrating the FDA/BP hold for HIV which I think will be lifted soon.
What happened with Leronlimab being trialed in combination with Keytruda (pembrolizumab) in a cancer in partnership with MD Anderson Cancer Center?
I don't see how a hold has any effect on the partnership or buyout if BP is the partner. Would Merck really have a problem lifting the hold? So we don't get top dollar without a hold lift, is that it?